Jianfeng Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jianfeng Li has a total of 628 co-authors. Here are the top co-authors by number of shared publications:
- Sai-Juan Chen
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
21 shared publications - Jian-Qing Mi
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Research Unit of Hematologic Malignancies Genomics and Translational Research of Chinese Academy of Medical Sciences, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
14 shared publications - Zhu Chen
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
12 shared publications - Jinyan Huang
Center for Biomedical Big Data, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
10 shared publications - Yuting Dai
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and School of Life Sciences & Biotechnology, Shanghai Jiao Tong University, Shanghai, China
9 shared publications - Shuxian Yao
Shanghai Institute of Hematology 1 , State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
8 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A Novel Nanobody-Based TCR-like CAR T Therapy Targeting PRAME for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 2. Distribution of PRAME mRNA expression in normal tissues and hematopoietic cells.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A Novel Nanobody-Based TCR-like CAR T Therapy Targeting PRAME for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 2. Distribution of PRAME mRNA expression in normal tissues and hematopoietic cells.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Novel Nanobody-Based TCR-like CAR T Therapy Targeting PRAME for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 1. The expression levels of PRAME in AML cell lines and its clinical relevance of PRAME expression in AML patients.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A Novel Nanobody-Based TCR-like CAR T Therapy Targeting PRAME for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 1. The expression levels of PRAME in AML cell lines and its clinical relevance of PRAME expression in AML patients.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from A Novel Nanobody-Based TCR-like CAR T Therapy Targeting PRAME for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 5. PR002 CAR-T cells exhibit minimal cytotoxicity against HSPCs.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from A Novel Nanobody-Based TCR-like CAR T Therapy Targeting PRAME for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 5. PR002 CAR-T cells exhibit minimal cytotoxicity against HSPCs.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A Novel Nanobody-Based TCR-like CAR T Therapy Targeting PRAME for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 3. Isolation strategy for PRAME425–433/HLA-A2-specific nanobodies.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A Novel Nanobody-Based TCR-like CAR T Therapy Targeting PRAME for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 3. Isolation strategy for PRAME425–433/HLA-A2-specific nanobodies.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Data from A Novel Nanobody-Based TCR-like CAR T Therapy Targeting PRAME for the Treatment of Acute Myeloid Leukemia
Purpose:Chimeric antigen receptor (CAR) T-cell immunotherapy in acute myeloid leukemia (AML) remains challenging because of the lack of specific cell surface antigens that are highly expressed on leukemic blasts but largely absent in hematopoietic stem/progenitor cells (HSPC) and healthy tissues. Targeting intracellular antigen via T-cell receptor (TCR)–like CAR T cells offers a promising alternative. This study aimed to develop nanobodies targeting the intracellular antigen preferentially expressed antigen in melanoma (PRAME) and develop a novel nanobody-based TCR-like CAR T-cell therapy.Experimental Design:We investigated the PRAME expression level by analyzing the RNA sequencing data from 1,007 patients with AML and healthy donor samples. We explored the relationships between PRAME expression and the prognosis of AML. Novel nanobodies targeting PRAME425–433/human leukocyte antigen A2 (HLA-A2) were generated via alpaca immunization and yeast surface display and then used to construct TCR-like CAR T cells. The antileukemia potency of the PRAME-targeted TCR-like CAR T cells and their on-target/off-tumor toxicity against normal HSPCs were evaluated.Results:PRAME was highly expressed in AML cells but largely absent in normal hematopoietic cells and healthy tissues and was correlated with poor clinical outcomes in AML. The CAR T cells based on the nanobody targeting PRAME425–433/HLA-A2 exhibited specific and potent antileukemic cytotoxicity against PRAME+HLA-A2+ AML cells in vitro and in vivo, whereas they showed negligible effects on the viability and function of normal HSPCs.Conclusions:This study demonstrates that PRAME is a promising target for the immunotherapy of AML, and nanobody-based TCR-like CAR T cells targeting PRAME425–433/HLA-A2 exhibit potent antileukemic activity with a favorable off-target safety profile.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Novel Nanobody-Based TCR-like CAR T Therapy Targeting PRAME for the Treatment of Acute Myeloid Leukemia
Purpose:Chimeric antigen receptor (CAR) T-cell immunotherapy in acute myeloid leukemia (AML) remains challenging because of the lack of specific cell surface antigens that are highly expressed on leukemic blasts but largely absent in hematopoietic stem/progenitor cells (HSPC) and healthy tissues. Targeting intracellular antigen via T-cell receptor (TCR)–like CAR T cells offers a promising alternative. This study aimed to develop nanobodies targeting the intracellular antigen preferentially expressed antigen in melanoma (PRAME) and develop a novel nanobody-based TCR-like CAR T-cell therapy.Experimental Design:We investigated the PRAME expression level by analyzing the RNA sequencing data from 1,007 patients with AML and healthy donor samples. We explored the relationships between PRAME expression and the prognosis of AML. Novel nanobodies targeting PRAME425–433/human leukocyte antigen A2 (HLA-A2) were generated via alpaca immunization and yeast surface display and then used to construct TCR-like CAR T cells. The antileukemia potency of the PRAME-targeted TCR-like CAR T cells and their on-target/off-tumor toxicity against normal HSPCs were evaluated.Results:PRAME was highly expressed in AML cells but largely absent in normal hematopoietic cells and healthy tissues and was correlated with poor clinical outcomes in AML. The CAR T cells based on the nanobody targeting PRAME425–433/HLA-A2 exhibited specific and potent antileukemic cytotoxicity against PRAME+HLA-A2+ AML cells in vitro and in vivo, whereas they showed negligible effects on the viability and function of normal HSPCs.Conclusions:This study demonstrates that PRAME is a promising target for the immunotherapy of AML, and nanobody-based TCR-like CAR T cells targeting PRAME425–433/HLA-A2 exhibit potent antileukemic activity with a favorable off-target safety profile.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A Novel Nanobody-Based TCR-like CAR T Therapy Targeting PRAME for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 4. Binding profiles of LL-PR002 evaluated by alanine scanning on T2 cells.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A Novel Nanobody-Based TCR-like CAR T Therapy Targeting PRAME for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 4. Binding profiles of LL-PR002 evaluated by alanine scanning on T2 cells.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from A Novel Nanobody-Based TCR-like CAR T Therapy Targeting PRAME for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 6. Effects of CAR-T cell therapy on target expression and body weight in xenograft models.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from A Novel Nanobody-Based TCR-like CAR T Therapy Targeting PRAME for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 6. Effects of CAR-T cell therapy on target expression and body weight in xenograft models.
- Open Access
- 19 May 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (21)
Molecular insight into the interplay among heterogeneous plasmacytes and microenvironment cells and their clinical relevance in myeloma
Multiple myeloma (MM) develops with the acquisition of genetic abnormalities in plasmacytes and changes in microenvironment cells (MECs). Despite the progress in understanding MM disease mechanism through omics studies, the genomic/transcriptomic profiling remains limited in Chinese MM patients. Here, we collected 277 newly diagnosed MM (NDMM) patients in the Shanghai MM Omics (SMMO) project. Analysis of 267 cases with whole-genome/whole-exome sequencing and RNA sequencing (RNA-seq) identified three genetic groups (MY, HRD, and MS/CD). Using single-cell RNA sequencing (scRNA-seq), we investigated 59 NDMM subjects from SMMO, 20 relapsed cases from public database and 30 normal controls. Eight subpopulations of plasmacytes from NDMM (mSP1–mSP8) were defined, each showing unique signatures while forming a differentiation trajectory. The mSP2 is worth noting due to its high proliferative property. Regarding MECs, we found T cell subsets including T-helpers, Tregs, and cytotoxic T cells all in dysfunctional status and increased myeloid-derived suppressor cells such as macrophages mainly in M2 polarization, both constituting a milieu in favor of MM cell growth and immune escape. Furthermore, we scrutinized the crosstalk between MM cells and MECs and that among distinct MECs. A dynamic, comprehensive MM pathogenesis network was revealed, with a number of ligand–receptor pairs. Importantly, the mSP2 signature can be projected to the MM cell RNA-seq data of 235 patients to generate a Score100 with prognostic value in SMMO. Via multivariate analysis of the International Staging System, Consensus Genomic Staging, and Score100, we propose a practical MM stratification model for evaluating aggressive myeloma.
- 19 May 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (21)
Open AccessMolecular insight into the interplay among heterogeneous plasmacytes and microenvironment cells and their clinical relevance in myeloma
Multiple myeloma (MM) develops with the acquisition of genetic abnormalities in plasmacytes and changes in microenvironment cells (MECs). Despite the progress in understanding MM disease mechanism through omics studies, the genomic/transcriptomic profiling remains limited in Chinese MM patients. Here, we collected 277 newly diagnosed MM (NDMM) patients in the Shanghai MM Omics (SMMO) project. Analysis of 267 cases with whole-genome/whole-exome sequencing and RNA sequencing (RNA-seq) identified three genetic groups (MY, HRD, and MS/CD). Using single-cell RNA sequencing (scRNA-seq), we investigated 59 NDMM subjects from SMMO, 20 relapsed cases from public database and 30 normal controls. Eight subpopulations of plasmacytes from NDMM (mSP1–mSP8) were defined, each showing unique signatures while forming a differentiation trajectory. The mSP2 is worth noting due to its high proliferative property. Regarding MECs, we found T cell subsets including T-helpers, Tregs, and cytotoxic T cells all in dysfunctional status and increased myeloid-derived suppressor cells such as macrophages mainly in M2 polarization, both constituting a milieu in favor of MM cell growth and immune escape. Furthermore, we scrutinized the crosstalk between MM cells and MECs and that among distinct MECs. A dynamic, comprehensive MM pathogenesis network was revealed, with a number of ligand–receptor pairs. Importantly, the mSP2 signature can be projected to the MM cell RNA-seq data of 235 patients to generate a Score100 with prognostic value in SMMO. Via multivariate analysis of the International Staging System, Consensus Genomic Staging, and Score100, we propose a practical MM stratification model for evaluating aggressive myeloma.
- Open Access
- 19 May 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1)
Targeting ZMIZ1 induces differentiation in acute myeloid leukemia via chromatin remodeling
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by profound transcriptional dysregulation and impaired hematopoietic differentiation. While differentiation therapy has revolutionized treatment in acute promyelocytic leukemia (APL), analogous strategies in non-APL AML remain elusive. Here, we identify ZMIZ1 (Zinc finger MIZ domain-containing protein 1) as a previously unrecognized transcriptional co-regulator that enforces differentiation blockade in AML from a targeted CRISPR-Cas9 screen. ZMIZ1 expression is elevated in AML patients and correlates with adverse outcomes. Genetic ablation of ZMIZ1 in leukemic cells induces terminal differentiation, reduces leukemia cell stemness, restores anti-leukemic immune responses, and significantly prolongs survival in murine AML models. Mechanistically, ZMIZ1 forms phase-separated nuclear condensates and maintains the super-enhancer architecture of genes critical for hematopoietic identity and immune evasion. Integrated Hi-C and ChIP-seq analyses reveal that ZMIZ1 cooperates with MEF2D (Myocyte-specific enhancer factor 2D) to promote enhancer-promoter looping and transcriptional output. Finally, we report the development of small-compounds potentially targeting ZMIZ1 with high binding affinity, selective on-target activity, and potent in vivo efficacy in both the murine AML model and AML organoids. Collectively, these findings uncover ZMIZ1 as a targetable epigenetic vulnerability in AML, underscoring its potential as a promising therapeutic target for differentiation-based treatment strategies.
- 19 May 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1)
Open AccessTargeting ZMIZ1 induces differentiation in acute myeloid leukemia via chromatin remodeling
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by profound transcriptional dysregulation and impaired hematopoietic differentiation. While differentiation therapy has revolutionized treatment in acute promyelocytic leukemia (APL), analogous strategies in non-APL AML remain elusive. Here, we identify ZMIZ1 (Zinc finger MIZ domain-containing protein 1) as a previously unrecognized transcriptional co-regulator that enforces differentiation blockade in AML from a targeted CRISPR-Cas9 screen. ZMIZ1 expression is elevated in AML patients and correlates with adverse outcomes. Genetic ablation of ZMIZ1 in leukemic cells induces terminal differentiation, reduces leukemia cell stemness, restores anti-leukemic immune responses, and significantly prolongs survival in murine AML models. Mechanistically, ZMIZ1 forms phase-separated nuclear condensates and maintains the super-enhancer architecture of genes critical for hematopoietic identity and immune evasion. Integrated Hi-C and ChIP-seq analyses reveal that ZMIZ1 cooperates with MEF2D (Myocyte-specific enhancer factor 2D) to promote enhancer-promoter looping and transcriptional output. Finally, we report the development of small-compounds potentially targeting ZMIZ1 with high binding affinity, selective on-target activity, and potent in vivo efficacy in both the murine AML model and AML organoids. Collectively, these findings uncover ZMIZ1 as a targetable epigenetic vulnerability in AML, underscoring its potential as a promising therapeutic target for differentiation-based treatment strategies.